Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Donald Kufe
Dana Farber Cancer Inst, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Genus Oncology
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Kufe is a co-inventor of the mucin protein “MUC1”. Genus Oncology (“the Company”), a privately held entity, has entered into an agreement with DFCI to license MUC1. Dr. Kufe holds equity in the Company serves on its Board of Directors, and serves as a scientific consultant. Dr. Kufe receives compensation for providing consulting services in the range of (b)(4) per year. The value of his equity cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
Dr. Kufe’s work on this project focuses on (i) investigations of potential mechanisms by which targeting MUC1-C suppresses PD-L1 expression in human EGFR and KRAS mutant NSCLC cells, (ii) the effects of targeting MUC1-C on expression of cytokines, and innate and adaptive immune-related genes, (iii) targeting MUC1-C in GEM models with antibody-drug conjugates and GO-203/nanoparticles, and (iv) the development of antibody-directed nanoparticle delivery. These studies involve use of the MUC1-C inhibitor, GO-203, which is licensed to the Company.
The Dana-Farber Cancer Institute (“DFCI”) has established this Conflict Management Plan based upon its understanding that the research involves use of a technology that is licensed to the Company, and that the proposed work, if successful, could potentially increase the valuation of the Company.
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung Cancer
Lung cancer is the leading cause of cancer deaths in the United States. The MUC1-C oncogenic protein is expressed at high levels in most non-small cell lung cancers (NSCLCs). Our proposed research addresses the premise that MUC1-C is of importance to evasion of immune destruction and is a novel target for the treatment of patients with NSCLC.
Filed on May 12, 2017.
Tell us what you know about Donald Kufe's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Donald Kufe filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $150,000 - $199,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $100,000 - $149,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $100,000 - $149,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $100,000 - $149,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | $0 - $4,999 |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
| Donald Kufe | Dana Farber Cancer Inst | Conflict of Interest | Genus Oncology | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.